Pulmovant is a Roivant-backed clinical-stage biotechnology company developing innovative therapies for patients suffering from pulmonary diseases. Pulmovant's first program, mosliciguat is designed to provide an effective, once-daily, inhaled treatment option for patients with pulmonary hypertension (PH). Mosliciguat is a novel, potential first-in-class, sGC activator with a differentiated mechanism that may have broad applicability across the PH spectrum.
Mosliciguat has been extensively characterized across a robust Phase 1 program with 170 participants dosed to date including patients with PH in the Phase 1b ATMOS study which has produced highly compelling and clinically meaningful efficacy data, as well as a favorable safety profile. Enrollment in a phase 2 trial is ongoing.
As part of the Roivant family of companies, Pulmovant leverages the power of collaboration and innovation to drive progress.
For more information, please visit
About Roivant:
Roivant specializes in developing transformative medicines at an accelerated pace through the launch of nimble biopharmaceutical and health technology entities, each meticulously tailored to address a specific medical need. Since its inception in 2014, Roivant has achieved the following critical milestones in support of its vision: built over 20 Vants; 12 consecutive positive Phase 3 trials; 8 FDA approvals; 5 successful IPOs; >$6B in capital raised; >$10B in global pharma partnerships and proceeds; and continued pipeline expansion across various modalities and therapeutic areas through in-licensing and acquisition of novel product candidates and technology platforms. In addition to a robust clinical stage pipeline, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Position: Head of Clinical Operations
Summary:
The Head of Clinical Operations will be responsible for establishing the clinical operations function for an incubating portfolio company (Vant) focused on development of first- and best- in class treatments in pulmonary diseases. S/he will lead and oversee execution of clinical program to progress programs forward within the portfolio. S/he will proactively identify and mitigate risks, lead from the front and collaborate with the Head of Clinical Development and SVP, Clinical Operations to improve timelines, ensure operational planning and execution excellences, and budgeting for the clinical program. This is an opportunity to play an instrumental role in bringing a novel therapy to market with blockbuster commercial potential while providing better treatment options for patients living with pulmonary diseases.
Key Duties and Responsibilities